Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Currently, the treatment for ocular neovascular diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. Although it can preserve vision, repeated injections are an invasive treatment modality, leading to serious complications and reducing patient adherence to treatment. To reduce the frequency of administration, prolong the time of drug action, and avoid repeated intravitreal injections, the combination of sustained-release materials with anti-VEGF drug therapy has become an emphasis in ophthalmology. In this review, we highlight the current state of anti-VEGF technology, its challenges, and the sustained-release strategies under investigation or being used in clinical practice. Both continuous release and considerable therapeutic effects can be achieved by encapsulating anti-VEGF drugs in sustained-release materials to minimize the number of intravitreal injections. At present, two sustained-release materials are being tested in clinical research, and although basic research shows the strong therapeutic application prospects of extended-release drugs, its challenges mainly involve the discrepancy between the release rates in vitro and the efficiency of the drugs in vivo. Briefly, sustained release of anti-VEGF agents is an advantageous strategy for treating retinal angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“VEGF is a key mediator of the pathological angiogenesis and the formation of macular choroidal neovascularisation (CNV) that, without intervention, is directly responsible for vision loss in nAMD.2,4,5,7”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aflibercept is an anti-VEGF recombinant fusion protein, which was FDA approved for nAMD in 2011 and has been administered intravitreally over 20 million times worldwide to treat VEGF-mediated retinal disorders.3,7”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, repeated intravitreal injections are invasive and risk potentially blinding complications (18).”
From Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Self-citationDe Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Cheung, N., Mitchell, P., & Wong, T. Y. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62124-3 · Cited by 3,288
Polymeric systems for controlled drug release
Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., & Shakesheff, K. M. (1999) · Chemical Reviews · doi:10.1021/cr940351u · Cited by 2,633 · cited 1×
“PLGA can be processed into virtually any shape and size, can encapsulate molecules of virtually any size, and is soluble in a variety of common solvents, including chlorinated solvents, tetrahydrofuran, acetone, and ethyl acetate.(109,110) In water, PLGA is biodegraded by the hydrolysis of ester bonds.”
BackgroundIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 2×
“Some studies have shown that delaying or reducing the number of injections can lead to varying degrees of vision loss.(55,73) The use of anti-VEGF drugs has changed the outlook for patients with retinal vascular diseases.”
BackgroundMethodChitosan-based hydrogels for controlled, localized drug delivery
Bhattarai, N., Gunn, J., & Zhang, M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.07.019 · Cited by 2,451
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Jain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Research works printed but not linked: 13
- Domańska-Janik, 1972, Neuropatol Pol, 10, 17
- Kim, 2018, Surv Ophthalmol, 63, 618, 10.1016/j.survophthal · doi:10.1016/j.survophthal
- Ferrara, 2006, Retina, 26, 859, 10.1097/01.iae.0000242842 · doi:10.1097/01.iae.0000242842
- Arrigo, 2021, Pharmaceutics, 13, 10.3390/pharmaceutics.13071102 · doi:10.3390/pharmaceutics.13071102
- Zhang, 2008, Mol Vis, 14, 37
- Chandrasekaran, 2021, Ther Adv Ophthalmol, 13, 25158414211027708, 10.1177/251.58414211027708 · doi:10.1177/251.58414211027708
- Liang, 2018, Invest Ophthalmol Vis Sci, 59, 211
- 2020, Angiogenesis, Exudation and Degeneration, 8 February 2020
- Tseng, 2012, J Glaucoma, 21, 241, 10.1097/ijg.0b013e31820.d7d19 · doi:10.1097/ijg.0b013e31820.d7d19
- Mouallem, 2016, Retina, 36, 2197, 10.1097/iae.0000.000000001062 · doi:10.1097/iae.0000.000000001062
- 2019, Hawaiian Eye & Retina Annual Meeting, January 21, 2019
- Pandit, 2017, Artif Cells Nanomed Biotechnol, 45, 1397, 10.1080/21691401.20161243545 · doi:10.1080/21691401.20161243545
- Nadarassan, 2014, Invest Ophthalmol Vis Sci, 55, 1950
Cited by
Items 101–118 of 118
Shrinkhal, Garg, P., Singh, S. P., & Shukla, A. (2026) · TNOA Journal of Ophthalmic Science and Research · doi:10.4103/tjosr.tjosr_111_26
Lee, A., Park, S., Strang, J., Braun, T., Yang, H., Naef, R., & Jung, H. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.07.067
Manjunatha, H. J., Mahalingappa, G., Varadaraju, S. R., Manjunath, S. H., Prashantha, K., Damle, A., Lee, C., & Kumar, A. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103288
Lysosomal channel TPC2 modulates microglia-endothelial signaling in choroidal angiogenesis
Lu, Y., Reschigna, A., Kynast, F., Yang, Z., Gerhardt, M., Kielkowski, P., Priglinger, S., Biel, M., & Michalakis, S. (2026) · Angiogenesis · doi:10.1007/s10456-026-10082-4
Mohanty, B., & Munshi, P. (2026) · Materials Advances · doi:10.1039/d6ma00285d
Chen, Q., Su, B., Xu, K., Li, L., & Chen, C. (2026) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.70108
The CD39-CD73-adenosine axis: a pivotal regulator of retinal homeostasis and diseases
Chen, X., Ji, J., Yao, J., Chen, P., Zhang, J., Liu, L., & Wen, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1893953
Huang, Y., Deng, Y., Tang, J., & Wang, J. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119929
Han, S., Li, K., Liu, C., Chen, F., & Kot-Cheung, S. K. (2026) · Materials & Design · doi:10.1016/j.matdes.2026.117099 · Cited by 1
Bai, S., & Sun, H. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1953347
Pan, J., Yang, K.-T., Zhang, J.-Q., Jin, Y., & Chen, J. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124708
Sikanen, T. (2025) · UEF eRepo (University of Eastern Finland)
Thakur, S., Pandey, N., Kujur, S., & Salam, J. (2026) · Public Health - Open Journal · doi:10.17140/phoj-11-802
Li, B., Chen, J., Zhu, J., Zhang, Q., Deng, H., Wen, H., Wang, Z., Sun, B., Li, J., Xu, F., et al. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111276
Hao, M., 游琼英, Wei, X., & Qin, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1974368
Cho, W. R., Koh, T.-Y., Yoon, J.-S., Jeon, H., Lee, J., Kim, M., Park, S., & Ha, K. (2026) · Antioxidants · doi:10.3390/antiox15111370
Troxerutin targets c-RAF to inhibit ERK signaling and protect against diabetic retinopathy
Wu, C., Wang, Q., Wu, W., Cao, Z., Chen, X., Yan, Y., Han, H., Du, Z., Yin, J., Yu, H., et al. (2026) · Visual Neuroscience · doi:10.48130/vns-0026-0043
Alzidan, K. (2026) · Food Science and Human Wellness · doi:10.26599/fshw.2026.9251297
Metadata
- Authors
- Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X.
- Affiliations
- Tianjin Medical University Eye Hospital (CN)
- Corresponding author
- Li, Xiaorong
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-09
- Volume
- Volume 16
- Pages
- 3241-3262
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC9512290
- OpenAlex
- W4296720485
- Cited by
- 111
- References
- 145
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 23 · 2023: 10
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Natural Science Foundation of China (82171085)
- Natural Science Foundation of Tianjin City (19JCZDJC64000)
- Tianjin Research Innovation Project for Postgraduate Students (2021YJSB271)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- VEGF inhibitors, sustained drug release, retinal angiogenesis, diabetic macular edema, age-related macular degeneration, intravitreal injection, ocular neovascular disease, drug encapsulation
- MeSH terms
- Bevacizumab, Ranibizumab, Delayed-Action Preparations, Diabetic Retinopathy, Humans, Macular Edema, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.